No CrossRef data available.
Article contents
Efficacy and safety of n-3 fatty acids supplementation on depression: a systematic review and dose–response meta-analysis of randomised controlled trials
Published online by Cambridge University Press: 20 September 2023
Abstract
We aimed to investigate the effectiveness of n-3 fatty acids supplementation on the risk of developing depression, depressive symptoms and remission of depression. We searched PubMed, Scopus and Web of Science from inception to December 2022 to find randomised trials of n-3 fatty acids supplementation in adults. We conducted random-effects meta-analyses to estimate standardised mean differences (SMD) and 95 % CI for continuous outcomes and risk difference and 95 % CI for binary outcomes. A total of sixty-seven trials were included. Each 1 g/d n-3 fatty acids supplementation significantly improved depressive symptoms in adults with and without depression (moderate-certainty evidence), with a larger improvement in patients with existing depression. Dose–response analyses indicated a U-shaped effect in patients with existing depression, with the greatest improvement at 1·5 g/d. The analysis showed that n-3 fatty acid supplementation significantly increased depression remission by 19 more per 100 in patients with depression (low-certainty evidence). Supplementation with n-3 fatty acids did not reduce the risk of developing depression among the general population, but it did improve the severity of depression among patients with existing depression.
- Type
- Systematic Review and Meta-Analysis
- Information
- Copyright
- © The Author(s), 2023. Published by Cambridge University Press on behalf of The Nutrition Society
References
Chen, P, Wang, S, Ji, J, et al. (2015) Risk factors and management of gestational diabetes. Cell Biochem Biophys 71, 689–694.CrossRefGoogle ScholarPubMed
Katschnig, H (2006) Quality of life in mental disorders: challenges for research and clinical practice. World Psychiatr 5, 139.Google ScholarPubMed
Rudisch, B & Nemeroff, CB (2003) Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatr 54, 227–240.CrossRefGoogle ScholarPubMed
Krishnan, KR (2000) Depression as a contributing factor in cerebrovascular disease. Am Heart J 140, 70–76.CrossRefGoogle ScholarPubMed
Carnethon, MR, Biggs, ML, Barzilay, JI, et al. (2007) Longitudinal association between depressive symptoms and incident type 2 diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med 167, 802–807.CrossRefGoogle ScholarPubMed
Lin, CH, Yen, YC, Chen, MC, et al. (2014) Depression and pain impair daily functioning and quality of life in patients with major depressive disorder. J Affect Disord 166, 173–178.CrossRefGoogle ScholarPubMed
Ferrari, AJ, Charlson, FJ, Norman, RE, et al. (2013) Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 10, e1001547.CrossRefGoogle ScholarPubMed
Bokslag, A, van Weissenbruch, M, Mol, BW, et al. (2016) Preeclampsia; short and long-term consequences for mother and neonate. Early Hum Dev 102, 47–50.CrossRefGoogle Scholar
Bodnar, LM & Wisner, KL (2005) Nutrition and depression: implications for improving mental health among childbearing-aged women. Biol Psychiatr 58, 679–685.CrossRefGoogle ScholarPubMed
Hibbeln, JR (1998) Fish consumption and major depression. Lancet 351, 1213.CrossRefGoogle ScholarPubMed
Parker, G, Gibson, NA, Brotchie, H, et al. (2006)
n-3 fatty acids and mood disorders. Am J Psychiatr 163, 969–978.CrossRefGoogle ScholarPubMed
Hakkarainen, R, Partonen, T, Haukka, J, et al. (2004) Is low dietary intake of n-3 fatty acids associated with depression? Am J Psychiatr 161, 567–569.CrossRefGoogle ScholarPubMed
Conklin, SM, Manuck, SB, Yao, JK, et al. (2007) High n-6 and low n-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom Med 69, 932–934.CrossRefGoogle Scholar
Liao, Y, Xie, B, Zhang, H, et al. (2019) Efficacy of n-3 PUFAs in depression: a meta-analysis. Transl Psychiatr 9, 190.CrossRefGoogle Scholar
Deane, KHO, Jimoh, OF, Biswas, P, et al. (2021)
n-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials. Br J Psychiatry 218, 135–142.CrossRefGoogle Scholar
Luo, X-D, Feng, J-S, Yang, Z, et al. (2020) High-dose n-3 polyunsaturated fatty acid supplementation might be more superior than low-dose for major depressive disorder in early therapy period: a network meta-analysis. BMC Psychiatr 20, 1–8.CrossRefGoogle ScholarPubMed
Higgins, JPT, Thomas, J, Chandler, J, et al. (2019) Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, Incorporated.CrossRefGoogle Scholar
Schünemann, HJ, Oxman, AD, Brozek, J et al. (2008) Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336, 1106–1110.CrossRefGoogle ScholarPubMed
Brenes, GA (2007) Anxiety, depression, and quality of life in primary care patients. Primary Care Companion J Clin Psychiatr 9, 437.CrossRefGoogle ScholarPubMed
Sterne, JA, Savović, J, Page, MJ, et al. (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898.CrossRefGoogle ScholarPubMed
Chandler, J, Cumpston, M, Li, T, et al. (2019) Cochrane Handbook for Systematic Reviews of Interventions. Hoboken: Wiley.Google Scholar
Higgins, JPT, Thomas, J, Chandler, J, et al. (2008) Selecting studies and collecting data. In Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series, pp. 151–185 [Higgins, JPT, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ & Welch, VA, editors]. West Sussex: John Wiley & Sons Ltd.CrossRefGoogle Scholar
Furukawa, TA, Barbui, C, Cipriani, A, et al. (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59, 7–10.CrossRefGoogle ScholarPubMed
Crippa, A & Orsini, N (2016) Dose-response meta-analysis of differences in means. BMC Med Res Method 16, 1–10.CrossRefGoogle ScholarPubMed
DerSimonian, R & Laird, N (1986) Meta-analysis in clinical trials. Control Clin Trials 7, 177–188.CrossRefGoogle ScholarPubMed
Borenstein, M (2019) Common Mistakes in Meta-Analysis and How to Avoid Them. Englewood, NJ: Biostat, Inc.Google Scholar
Schandelmaier, S, Briel, M, Varadhan, R, et al. (2020) Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. Cmaj 192, E901–E906.CrossRefGoogle ScholarPubMed
Egger, M, Davey Smith, G, Schneider, M, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634.CrossRefGoogle ScholarPubMed
Begg, CB & Mazumdar, M (1994) Operating characteristics of a rank correlation test for publication bias. Biom 50, 1088–1101.CrossRefGoogle Scholar
Higgins, JPT, Sterne, JAC, Page, MJ, et al. (2019) Assessing risk of bias in a randomized trial. In Cochrane Handbook for Systematic Reviews of Interventions, pp. 205–228 [Higgins, JPT, Churchill, R, Chandler, J, Cumpston, MS, editors]. West Sussex: John Wiley & Sons Ltd.CrossRefGoogle Scholar
DerSimonian, R & Laird, N (1986) Meta-analysis in clinical trials. Controlled Clin Trial 7, 177–188.CrossRefGoogle ScholarPubMed
Higgins, JP, Thompson, SG, Deeks, JJ, et al. (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557–560.CrossRefGoogle ScholarPubMed
Crippa, A, Discacciati, A, Bottai, M, et al. (2019) One-stage dose–response meta-analysis for aggregated data. Stat Methods Med Res 28, 1579–1596.CrossRefGoogle ScholarPubMed
Orsini, N, Li, R, Wolk, A, et al. (2012) Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 175, 66–73.CrossRefGoogle ScholarPubMed
Guyatt, GH, Oxman, AD, Kunz, R, et al. (2011) GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 64, 1283–1293.CrossRefGoogle ScholarPubMed
Hopkins, W, Marshall, S, Batterham, A, et al. (2009) Progressive statistics for studies in sports medicine and exercise science. Medicine + Sci Sports + Exercise 41, 3.CrossRefGoogle ScholarPubMed
Varangot-Reille, C, Suso-Martí, L, Romero-Palau, M, et al. (2021) Effects of different therapeutic exercise modalities on migraine or tension-type headache: a systematic review and meta-analysis with a replicability analysis. J Pain 23, 1099–1122.CrossRefGoogle ScholarPubMed
Andrieu, S, Guyonnet, S, Coley, N, et al. (2017) Effect of long-term n-3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16, 377–389.CrossRefGoogle ScholarPubMed
Antypa, N, Smelt, AH, Strengholt, A, et al. (2012) Effects of n-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals. J Psychopharmacol 26, 738–743.CrossRefGoogle ScholarPubMed
Bellino, S, Bozzatello, P, Rocca, G, et al. (2014) Efficacy of n-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol 28, 125–132.CrossRefGoogle ScholarPubMed
Bot, M, Pouwer, F, Assies, J, et al. (2010) Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J Affect Disord 126, 282–286.CrossRefGoogle ScholarPubMed
Bradbury, J, Myers, SP, Meyer, B, et al. (2017) Chronic psychological stress was not ameliorated by n-3 eicosapentaenoic acid (EPA). Front Pharmacol 8, 551.CrossRefGoogle ScholarPubMed
Carney, RM, Freedland, KE, Rubin, EH, et al. (2009)
n-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 302, 1651–1657.CrossRefGoogle Scholar
Carney, RM, Freedland, KE, Rubin, EH, et al. (2019) A randomized placebo-controlled trial of n-3 and sertraline in depressed patients with or at risk for coronary heart disease. J Clin Psychiatr 80, 13302.CrossRefGoogle ScholarPubMed
Carney, RM, Freedland, KE, Stein, PK, et al. (2010) The effect of n-3 fatty acids on heart rate variability in depressed patients with coronary heart disease. Psychosomatic Med 72, 748.CrossRefGoogle ScholarPubMed
Chang, JP, Chang, SS, Yang, HT, et al. (2020)
n-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder - results from a randomized controlled trial. Brain Behav Immun 85, 14–20.CrossRefGoogle ScholarPubMed
Chew, EY, Clemons, TE, Agrón, E, et al. (2015) Effect of n-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA 314, 791–801.CrossRefGoogle ScholarPubMed
Cohen, LS, Joffe, H, Guthrie, KA, et al. (2014) Efficacy of n-3 treatment for vasomotor symptoms: a randomized controlled trial: n-3 treatment for vasomotor symptoms. Menopause (New York, NY) 21, 347.CrossRefGoogle Scholar
da Silva, TM, Munhoz, RP, Alvarez, C, et al. (2008) Depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled pilot study of n-3 fatty-acid supplementation. J Affect Disord 111, 351–359.CrossRefGoogle Scholar
Dangour, AD, Allen, E, Elbourne, D, et al. (2010) Effect of 2-year n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 91, 1725–1732.CrossRefGoogle Scholar
Dashti-Khavidaki, S, Gharekhani, A, Khatami, M-R, et al. (2014) Effects of n-3 fatty acids on depression and quality of life in maintenance hemodialysis patients. Am J Therapeutics 21, 275–287.CrossRefGoogle ScholarPubMed
Derosa, G, Cicero, AF, D’Angelo, A, et al. (2016) Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. Biofactors 42, 316–322.CrossRefGoogle ScholarPubMed
Dretsch, MN, Johnston, D, Bradley, RS, et al. (2014) Effects of n-3 fatty acid supplementation on neurocognitive functioning and mood in deployed US soldiers: a pilot study. Mil Med 179, 396–403.CrossRefGoogle ScholarPubMed
Ferreira, JJ, Rosser, A, Craufurd, D, et al. (2015) Ethyl-eicosapentaenoic acid treatment in Huntington’s disease: a placebo-controlled clinical trial. Mov Disord 30, 1426–1429.CrossRefGoogle ScholarPubMed
Gertsik, L, Poland, RE, Bresee, C, et al. (2012)
n-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 32, 61.CrossRefGoogle ScholarPubMed
Gharekhani, A, Khatami, M-R, Dashti-Khavidaki, S, et al. (2014) The effect of n-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol 70, 655–665.CrossRefGoogle ScholarPubMed
Giltay, EJ, Geleijnse, JM & Kromhout, D (2011) Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. Am J Clin Nutr 94, 1442–1450.CrossRefGoogle ScholarPubMed
Ginty, AT, Muldoon, MF, Kuan, DC, et al. (2017)
n-3 supplementation and the neural correlates of negative affect and impulsivity: a double-blind, randomized, placebo-controlled trial in midlife adults. Psychosomatic Med 79, 549.CrossRefGoogle Scholar
Group ASC (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 379, 1540–1550.CrossRefGoogle Scholar
Haberka, M, Mizia-Stec, K, Mizia, M, et al. (2013) Effects of n-3 polyunsaturated fatty acids on depressive symptoms, anxiety and emotional state in patients with acute myocardial infarction. Pharmacol Rep 65, 59–68.CrossRefGoogle Scholar
Hallahan, B, Hibbeln, JR, Davis, JM, et al. (2007)
n-3 fatty acid supplementation in patients with recurrent self-harm: single-centre double-blind randomised controlled trial. Br J Psychiatr 190, 118–122.CrossRefGoogle ScholarPubMed
Hashimoto, M, Kato, S, Tanabe, Y, et al. (2017) Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing homes. Geriatr Gerontol Int 17, 330–337.CrossRefGoogle ScholarPubMed
Investigators HSGT-H (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65, 1582–1589.Google Scholar
Jackson, PA, Deary, ME, Reay, JL, et al. (2012) No effect of 12 weeks’ supplementation with 1 g DHA-rich or EPA-rich fish oil on cognitive function or mood in healthy young adults aged 18–35 years. Br J Nutr 107, 1232–1243.CrossRefGoogle ScholarPubMed
Jahangard, L, Sadeghi, A, Ahmadpanah, M, et al. (2018) Influence of adjuvant n-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders-Results from a double-blind, randomized and placebo-controlled clinical trial. J Psychiatr Res 107, 48–56.CrossRefGoogle Scholar
Jiang, W, Whellan, DJ, Adams, KF, et al. (2018) Long-chain n-3 fatty acid supplements in depressed heart failure patients: results of the OCEAN trial. JACC: Heart Failure 6, 833–843.Google ScholarPubMed
Kiecolt-Glaser, JK, Belury, MA, Andridge, R, et al. (2011)
n-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain, Behav, Immun 25, 1725–1734.CrossRefGoogle ScholarPubMed
Kromhout, D, Giltay, EJ & Geleijnse, JM (2010)
n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363, 2015–2026.CrossRefGoogle ScholarPubMed
Lee, LK, Shahar, S, Chin, A-V, et al. (2013) Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacol 225, 605–612.CrossRefGoogle ScholarPubMed
Lespérance, F, Frasure-Smith, N, St-André, E, et al. (2010) The efficacy of n-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatr 71, 6074.Google Scholar
Lucas, M, Asselin, G, Mérette, C, et al. (2009) Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 89, 641–651.CrossRefGoogle ScholarPubMed
Maltais, M, de Souto Barreto, P, Pothier, K, et al. (2019) Lifestyle multidomain intervention, n-3 supplementation, or both for reducing the risk of developing clinically relevant depressive symptoms in older adults with memory complaints? Secondary analysis from the MAPT trial. Exp Gerontol 120, 28–34.CrossRefGoogle ScholarPubMed
Marangell, LB, Martinez, JM, Zboyan, HA, et al. (2003) A double-blind, placebo-controlled study of the n-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160, 996–998.CrossRefGoogle ScholarPubMed
Masoumi, SZ, Kazemi, F, Tavakolian, S, et al. (2016) Effect of citalopram in combination with n-3 on depression in post-menopausal women: a triple blind randomized controlled trial. J Clin Diagn Res: JCDR 10, QC01.CrossRefGoogle Scholar
Mazaherioun, M, Saedisomeolia, A, Javanbakht, MH, et al. (2018) Long chain n-3 fatty acids improve depression syndrome in type 2 diabetes mellitus. Iranian J Public Health 47, 575.Google ScholarPubMed
Mazereeuw, G, Herrmann, N, Oh, PI, et al. (2016)
n-3 fatty acids, depressive symptoms, and cognitive performance in patients with coronary artery disease: analyses from a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 36, 436.CrossRefGoogle ScholarPubMed
McGorry, PD, Nelson, B, Markulev, C, et al. (2017) Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatr 74, 19–27.CrossRefGoogle ScholarPubMed
McPhilemy, G, Byrne, F, Waldron, M, et al. (2021) A 52-week prophylactic randomised control trial of n-3 polyunsaturated fatty acids in bipolar disorder. Bipolar Disord 23, 697–706.CrossRefGoogle Scholar
Mozaffari-Khosravi, H, Yassini-Ardakani, M, Karamati, M, et al. (2013) Eicosapentaenoic acid v. docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 23, 636–644.CrossRefGoogle Scholar
Nemets, B, Stahl, Z & Belmaker, R (2002) Addition of n-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatr 159, 477–479.CrossRefGoogle ScholarPubMed
Park, Y, Park, Y-S, Kim, SH, et al. (2015) Supplementation of n-3 polyunsaturated fatty acids for major depressive disorder: a randomized, double-blind, 12-week, placebo-controlled trial in Korea. Ann Nutr Metab 66, 141–148.CrossRefGoogle ScholarPubMed
Pawełczyk, T, Grancow-Grabka, M, Kotlicka-Antczak, M, et al. (2016) A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in n-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 73, 34–44.CrossRefGoogle Scholar
Pomponi, M, Loria, G, Salvati, S, et al. (2014) DHA effects in Parkinson disease depression. Basal Ganglia 4, 61–66.CrossRefGoogle Scholar
Poppitt, SD, Howe, CA, Lithander, FE, et al. (2009) Effects of moderate-dose n-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial. Stroke 40, 3485–3492.CrossRefGoogle Scholar
Pratt, CM, Reiffel, JA, Ellenbogen, KA, et al. (2009) Efficacy and safety of prescription n-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am na journal 158, 163–169. e163.Google Scholar
Rauch, B, Schiele, R, Schneider, S, et al. (2010) OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified n-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122, 2152–2159.CrossRefGoogle Scholar
Ravi, S, Khalili, H, Abbasian, L, et al. (2016) Effect of n-3 fatty acids on depressive symptoms in hiv-positive individuals: a randomized, placebo-controlled clinical trial. Ann Pharmacother 50, 797–807.CrossRefGoogle ScholarPubMed
Rizzo, AM, Corsetto, PA, Montorfano, G, et al. (2012) Comparison between the AA/EPA ratio in depressed and non depressed elderly females: n-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters. Nutr J 11, 1–11.CrossRefGoogle Scholar
Robinson, DG, Gallego, JA, John, M, et al. (2019) A potential role for adjunctive n-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Schizophr Res 204, 295–303.CrossRefGoogle Scholar
Rondanelli, M, Giacosa, A, Opizzi, A, et al. (2010) Effect of n-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr 29, 55–64.CrossRefGoogle ScholarPubMed
Sanyal, AJ, Abdelmalek, MF, Suzuki, A, et al. (2014) No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 147, 377–384. e371.CrossRefGoogle Scholar
Shinto, L, Marracci, G, Mohr, DC, et al. (2016)
n-3 fatty acids for depression in multiple sclerosis: a randomized pilot study. PLoS One 11, e0147195.CrossRefGoogle ScholarPubMed
Silvers, KM, Woolley, CC, Hamilton, FC, et al. (2005) Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins, Leukotrienes Essent Fatty Acids 72, 211–218.CrossRefGoogle ScholarPubMed
Sinn, N, Milte, CM, Street, SJ, et al. (2012) Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 107, 1682–1693.CrossRefGoogle Scholar
Sohrabi, N, Kashanian, M, Ghafoori, SS, et al. (2013) Evaluation of the effect of n-3 fatty acids in the treatment of premenstrual syndrome: ‘a pilot trial’. Complementary therapies medicine 21, 141–146.CrossRefGoogle ScholarPubMed
Su, K-P, Huang, S-Y, Chiu, C-C, et al. (2003)
n-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 13, 267–271.CrossRefGoogle ScholarPubMed
Su, KP, Lai, HC, Yang, HT, et al. (2014)
n-3 fatty acids in the prevention of interferon-
α
-induced depression: results from a randomized, controlled trial. Biol Psychiatr 76, 559–566.CrossRefGoogle ScholarPubMed
Tajalizadekhoob, Y, Sharifi, F, Fakhrzadeh, H, et al. (2011) The effect of low-dose n 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur Arch Psychiatr Clin Neurosci 261, 539–549.CrossRefGoogle ScholarPubMed
Tayama, J, Ogawa, S, Nakaya, N, et al. (2019)
n-3 polyunsaturated fatty acids and psychological intervention for workers with mild to moderate depression: a double-blind randomized controlled trial. J Affect Disord 245, 364–370.CrossRefGoogle Scholar
Torkildsen, O, Wergeland, S, Bakke, S, et al. (2012) ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 69, 1044–1051.CrossRefGoogle ScholarPubMed
van de Rest, O, Geleijnse, JM, Kok, FJ, et al. (2008) Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 88, 706–713.CrossRefGoogle ScholarPubMed
Watanabe, N, Matsuoka, Y, Kumachi, M, et al. (2018)
n-3 fatty acids for a better mental state in working populations-Happy Nurse Project: a 52-week randomized controlled trial. J Psychiatr Res 102, 72–80.CrossRefGoogle Scholar
Yurko-Mauro, K, McCarthy, D, Rom, D, et al. (2010) Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer’s Dementia 6, 456–464.CrossRefGoogle ScholarPubMed
Zanarini, MC & Frankenburg, FR (2003)
n-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatr 160, 167–169.CrossRefGoogle ScholarPubMed
Chang, JP-C, Chen, Y-T & Su, K-P (2009)
n-3 polyunsaturated fatty acids (n-3 PUFAs) in cardiovascular diseases (CVDs) and depression: the missing link? Cardiovasc Psychiatr Neurol 2009, 725310.CrossRefGoogle ScholarPubMed
Geleijnse, JM, Giltay, EJ & Kromhout, D (2012) Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimer’s Dementia 8, 278–287.CrossRefGoogle ScholarPubMed
Hallahan, B, Ryan, T, Hibbeln, JR, et al. (2016) Efficacy of n-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatr 209, 192–201.CrossRefGoogle Scholar
Martins, JG (2009) EPA but not DHA appears to be responsible for the efficacy of n-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 28, 525–542.CrossRefGoogle ScholarPubMed
Mocking, RJ, Harmsen, I, Assies, J, et al. (2016) Meta-analysis and meta-regression of n-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatr 6, e756.CrossRefGoogle ScholarPubMed
Grosso, G, Micek, A, Marventano, S, et al. (2016) Dietary n-3 PUFA, fish consumption and depression: a systematic review and meta-analysis of observational studies. J Affect Disord 205, 269–281.CrossRefGoogle ScholarPubMed
Yang, Y, Kim, Y & Je, Y (2018) Fish consumption and risk of depression: epidemiological evidence from prospective studies. Asia-Pac Psychiatr 10, e12335.CrossRefGoogle ScholarPubMed
Browning, LM, Walker, CG, Mander, AP, et al. (2012) Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 96, 748–758.CrossRefGoogle ScholarPubMed
Mori, TA (2014)
n-3 fatty acids and cardiovascular disease: epidemiology and effects on cardiometabolic risk factors. Food Funct 5, 2004–2019.CrossRefGoogle ScholarPubMed
Guu, T-W, Mischoulon, D, Sarris, J, et al. (2019) International society for nutritional psychiatry research practice guidelines for n-3 fatty acids in the treatment of major depressive disorder. Psychother Psychosom 88, 263–273.CrossRefGoogle ScholarPubMed
Chang, C-H, Tseng, P-T, Chen, N-Y, et al. (2018) Safety and tolerability of prescription n-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins, Leukotrienes Essent Fatty Acids 129, 1–12.CrossRefGoogle ScholarPubMed
Peoples, GE, McLennan, PL, Howe, PR, et al. (2008) Fish oil reduces heart rate and oxygen consumption during exercise. J Cardiovasc Pharmacol 52, 540–547.CrossRefGoogle ScholarPubMed
McManus, S, Tejera, N, Awwad, K, et al. (2016) Differential effects of EPA v. DHA on postprandial vascular function and the plasma oxylipin profile in men. J Lipid Res 57, 1720–1727.CrossRefGoogle Scholar
Krebs, J, Browning, L, McLean, N, et al. (2006) Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int J Obes 30, 1535–1544.CrossRefGoogle ScholarPubMed
Chong, MF-F, Lockyer, S, Saunders, CJ, et al. (2010) Long chain n-3 PUFA-rich meal reduced postprandial measures of arterial stiffness. Clin Nutr 29, 678–681.CrossRefGoogle ScholarPubMed
Armah, CK, Jackson, KG, Doman, I, et al. (2008) Fish oil fatty acids improve postprandial vascular reactivity in healthy men. Clin Sci 114, 679–686.CrossRefGoogle ScholarPubMed
Buckley, R, Shewring, B, Turner, R, et al. (2004) Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr 92, 477–483.CrossRefGoogle ScholarPubMed
Nicholls, SJ, Lincoff, AM, Garcia, M, et al. (2020) Effect of high-dose n-3 fatty acids v. corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 324, 2268–2280.CrossRefGoogle Scholar
Rapaport, MH, Nierenberg, AA, Schettler, PJ, et al. (2016) Inflammation as a predictive biomarker for response to n-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatr 21, 71–79.CrossRefGoogle ScholarPubMed
Kodas, E, Galineau, L, Bodard, S, et al. (2004) Serotoninergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat. J Neurochem 89, 695–702.CrossRefGoogle ScholarPubMed
Fountoulakis, KN, McIntyre, RS & Carvalho, AF (2015) From randomized controlled trials of antidepressant drugs to the meta-analytic synthesis of evidence: methodological aspects lead to discrepant findings. Curr Neuropharmacol 13, 605–615.CrossRefGoogle Scholar
Jones, BDM, Razza, LB, Weissman, CR, et al. (2021) Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Netw Open 4, e2125531.CrossRefGoogle ScholarPubMed
Furukawa, TA, Cipriani, A, Atkinson, LZ, et al. (2016) Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatr 3, 1059–1066.CrossRefGoogle ScholarPubMed
Rabkin, JG, Markowitz, JS, Stewart, J, et al. (1986) How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatr Res 19, 75–86.CrossRefGoogle Scholar
Papakostas, GI & Fava, M (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19, 34–40.CrossRefGoogle ScholarPubMed
Rutherford, BR, Wall, MM, Brown, PJ, et al. (2017) Patient expectancy as a mediator of placebo effects in antidepressant clinical trials. Am J Psychiatr 174, 135–142.CrossRefGoogle ScholarPubMed
Bourre, J-M, Dumont, O, Piciotti, M, et al. (1991) Essentiality of ω3 fatty acids for brain structure and function. World Rev Nutr Diet 66, 103–117.CrossRefGoogle Scholar
Yehuda, S, Rabinovitz, S & Mostofsky, DI (1998) Modulation of learning and neuronal membrane composition in the rat by essential fatty acid preparation: time-course analysis. Neurochem Res 23, 627–634.CrossRefGoogle ScholarPubMed
Heron, DS, Shinitzky, M, Hershkowitz, M, et al. (1980) Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc Natl Acad Sci 77, 7463–7467.CrossRefGoogle Scholar
Maes, M & Smith, RS (1998) Fatty acids, cytokines, and major depression. Biol Psychiatr 43, 313–314.Google ScholarPubMed
Suarez, EC, Krishnan, RR & Lewis, JG (2003) The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med 65, 362–368.CrossRefGoogle ScholarPubMed
Shimizu, E, Hashimoto, K, Okamura, N, et al. (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatr 54, 70–75.CrossRefGoogle ScholarPubMed
Norouziasl et al. supplementary material
Tables S1-S14 and Figures S1-S22
File
374.2 KB